Contact System Activation in Patients with HAE and Normal C1Inhibitor Function

Immunology and Allergy Clinics of North America

Volumn 33, Issue 4, 2013, Pages 513-533

  Ghannam, Arije ^a,b   Defendi, Federica ^a,b   Charignon, Delphine ^a,b   Csopaki, Françoise ^b   Favier, Bertrand ^a   Habib, Mohammed ^a   Cichon, Sven ^c   Drouet, Christian ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b French Reference Centre of Kinin Mediated Angio Oedemas   (France)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Contact phase; Factor XII; Kallikrein; Kinin forming enzymes; Kininogen

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALPHA 2 MACROGLOBULIN; AMIDASE; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 12; BRADYKININ; CHONDROITIN SULFATE; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; DEXTRAN SULFATE; GLYCOSAMINOGLYCAN; INFUSORIAL EARTH; KALLIKREIN; KAOLIN; KININ; KININOGEN; PLASMA KALLIKREIN; PREKALLIKREIN; PROTEINASE; SERINE PROTEINASE INHIBITOR; TISSUE KALLIKREIN; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; BLOOD CLOTTING; DISEASE CLASSIFICATION; ENDOTHELIUM; ENZYME ACTIVATION; F12 GENE; FIBRINOLYSIS; GENETIC LINKAGE; HUMAN; INFLAMMATION; ISCHEMIA; MAST CELL; MISSENSE MUTATION; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

CONTACT PHASE; FACTOR XII; KALLIKREIN; KININ FORMING ENZYMES; KININOGEN;

ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; ENZYME ACTIVATION; HUMANS; KALLIKREINS; KININS; PATIENT OUTCOME ASSESSMENT; PROTEOLYSIS;

EID: 84886721308     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2013.07.007     Document Type: Review

References (91)

1. Schapira M., Silver L.D., Scott C.F., et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. NEngl J Med 1983, 308:1050-1053.
2. Björkqvist J., Sala-Cunill A., Renné T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013, 109:368-374.
3. Moreau M.E., Garbacki N., Molinaro G., et al. The kallikrein-kinin system: current and future pharmacological targets. JPharmacol Sci 2005, 99:6-38.
4. Bas M., Adams V., Suvorava T., et al. Nonallergic angioedema: role of bradykinin. Allergy 2007, 62:842-856.
5. Renné T., Gruber A. Plasma kallikrein: novel functions for an old protease. Thromb Haemost 2012, 107:1012-1013.
6. Curd J.G., Prograis L.J., Cochrane C.G. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. JExp Med 1980, 152:742-747.
7. Cugno M., Zanichelli A., Foieni F., et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009, 15:69-78.
8. Caballero T., Baeza M.L., Cabañas R., et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. JInvestig Allergol Clin Immunol 2011, 21:333-347. [quiz: 347].
9. Martin L., Degenne D., Toutain A., et al. Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. JAllergy Clin Immunol 2001, 107:747-748.
10. Bork K., Barnstedt S.E., Koch P., et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000, 356:213-217.
11. Binkley K.E., Davis A. Clinical, biochemical, and genetic characterization of anovel estrogen-dependent inherited form of angioedema. JAllergy Clin Immunol 2000, 106:546-550.
12. Cichon S., Martin L., Hennies H.C., et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006, 79:1098-1104.
13. Bork K. Hereditary angioedema with normal C1 inhibition. Curr Allergy Asthma Rep 2009, 9:280-285.
14. Martin L., Raison-Peyron N., Nöthen M.M., et al. Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. JAllergy Clin Immunol 2007, 120:975-977.
15. Zuraw B.L., Bork K., Binkley K.E., et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc 2012, 33(Suppl 1):S145-S156.
16. Vitrat-Hincky V., Gompel A., Dumestre-Perard C., et al. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 2010, 65:1331-1336.
17. Defendi F., Charignon D., Ghannam A., et al. Enzymatic assays for the biological diagnosis of bradykinin-dependent angioedema. PLoS One 2013, 8:e70140.
18. Colman R.W. Contact activation (Kallikrein-Kinin) pathway: multiple physiologic and pathophysiologic activities. Hemostasis and thrombosis. Basic principles and clinical practice 2006, 109-113. Lippincott Williams & Wilkins, Philadelphia. R.W. Colman, V.J. Marder, A.W. Clowes (Eds.).
19. Shariat-Madar Z., Mahdi F., Schmaier A.H. Factor XI assembly and activation on human umbilical vein endothelial cells in culture. Thromb Haemost 2001, 85:544-551.
20. Colman R.W., Schmaier A.H. The contact activation system: biochemistry and interactions of these surface-mediated defense reactions. Crit Rev Oncol Hematol 1986, 5:57-85.
21. Kaufmann J., Haasemann M., Modrow S., et al. Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties. JBiol Chem 1993, 268:9079-9091.
22. Jiang Y.P., Muller-Esterl W., Schmaier A.H. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. JBiol Chem 1992, 267:3712-3717.
23. Renné T., Dedio J., David G., et al. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. JBiol Chem 2000, 275:33688-33696.
24. Shariat-Madar Z., Schmaier A.H. Kininogen-cytokeratin 1 interactions in endothelial cell biology. Trends Cardiovasc Med 1999, 9:238-244.
25. Tait J.F., Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. JBiol Chem 1987, 262:11651-11656.
26. Silverberg M., Nicoll J.E., Kaplan A.P. The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thromb Res 1980, 20:173-189.
27. Adam A., Albert A., Calay G., et al. Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values. Clin Chem 1985, 31:423-426.
28. Schmaier A.H. The elusive physiologic role of Factor XII. JClin Invest 2008, 118:3006-3009.
29. Farsetti A., Misiti S., Citarella F., et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995, 136:5076-5083.
30. Stavrou E., Schmaier A.H. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010, 125:210-215.
31. Samuel M., Pixley R.A., Villanueva M.A., et al. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. JBiol Chem 1992, 267:19691-19697.
32. Beaubien G., Rosinski-Chupin I., Mattei M.G., et al. Gene structure and chromosomal localization of plasma kallikrein. Biochemistry 1991, 30:1628-1635.
33. Schmaier A.H., McCrae K.R. The plasma kallikrein-kinin system: its evolution from contact activation. JThromb Haemost 2007, 5:2323-2329.
34. Clements J.A., Willemsen N.M., Myers S.A., et al. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004, 41:265-312.
35. Clements J.A. Reflections on the tissue kallikrein and kallikrein-related peptidase family - from mice to men - what have we learnt in the last two decades?. Biol Chem 2008, 389:1447-1454.
36. Zhou G.X., Chao L., Chao J. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. JBiol Chem 1992, 267:25873-25880.
37. Yin H., Gao L., Shen Bo, et al. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension 2010, 56:260-267.
38. Shariat-Madar Z., Mahdi F., Schmaier A.H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. JBiol Chem 2002, 277:17962-17969.
39. Renné T., Schuh K., Müller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. JImmunol 2005, 175:3377-3385.
40. Bergamaschini L., Donarini C., Foddi C., et al. The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol Aging 2001, 22:63-69.
41. Castaldi P.A., Larrieu M.J., Caen J. Availability of platelet factor 3 and activation of factor XII in thrombasthenia. Nature 1965, 207:422-424.
42. Johne J., Blume C., Benz P.M., et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem 2006, 387:173-178.
43. Müller F., Mutch N.J., Schenk W.A., et al. Platelet polyphosphates are proinflammatory and procoagulant mediators invivo. Cell 2009, 139:1143-1156.
44. Siebeck M., Cheronis J.C., Fink E., et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. JAppl Physiol 1994, 77:2675-2680.
45. Guerrini M., Beccati D., Shriver Z., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008, 26:669-675.
46. Kishimoto T.K., Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. NEngl J Med 2008, 358:2457-2467.
47. Hojima Y., Cochrane C.G., Wiggins R.C., et al. Invitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984, 63:1453-1459.
48. Baumgarten C.R., Linz W., Kunkel G., et al. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 1993, 108:293-295.
49. Lamontagne D., Nadeau R., Adam A. Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischaemic rat heart. Br J Pharmacol 1995, 115:476-478.
50. Cayla C., Todiras M., Iliescu R., et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 2007, 21:1689-1698.
51. Stoves J., Goode N.P., Visvanathan R., et al. The bradykinin response and early hypotension at the introduction of continuous renal replacement therapy in the intensive care unit. Artif Organs 2001, 25:1009-1013.
52. Joseph K., Tholanikunnel B.G., Kaplan A.P. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 2002, 99:896-900.
53. Kaplan A.P., Kay A.B., Austen K.F. Aprealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. JExp Med 1972, 135:81-97.
54. Schapira M., Despland E., Scott C.F., et al. Purified human plasma kallikrein aggregates human blood neutrophils. JClin Invest 1982, 69:1199-1202.
55. Wachtfogel Y.T., Kucich U., James H.L., et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. JClin Invest 1983, 72:1672-1677.
56. Wachtfogel Y.T., Pixley R.A., Kucich U., et al. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986, 67:1731-1737.
57. Ehrenfeld P., Millan C., Matus C.E., et al. Activation of kinin B1 receptors induces chemotaxis of human neutrophils. JLeukoc Biol 2006, 80:117-124.
58. Duchene J., Lecomte F., Ahmed S., et al. Anovel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. JImmunol 2007, 179:4849-4856.
59. Wachtfogel Y.T., DeLa Cadena R.A., Kunapuli S.P., et al. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). JBiol Chem 1994, 269:19307-19312.
60. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992, 44:1-80.
61. Imamura T., Dubin A., Moore W., et al. Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab Invest 1996, 74:861-870.
62. Lauredo I.T., Forteza R.M., Botvinnikova Y., et al. Leukocytic cell sources of airway tissue kallikrein. Am J Physiol Lung Cell Mol Physiol 2004, 286:L734-L740.
63. Forsberg E., Pejler G., Ringvall M., et al. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 1999, 400:773-776.
64. Bouillet L., Ponard D., Rousset H., et al. Acase of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 2007, 156:1063-1065.
65. Cugno M., Cicardi M., Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. JAllergy Clin Immunol 1994, 93:870-876.
66. Kluft C., Trumpi-Kalshoven M.M., Jie A.F., et al. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator. Thromb Haemost 1979, 41:756-773.
67. Brown N.J., Gainer J.V., Stein C.M., et al. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999, 33:1431-1435.
68. Kleniewski J., Blankenship D.T., Cardin A.D., et al. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. JLab Clin Med 1992, 120:129-139.
69. Du-Thanh A., Raison-Peyron N., Drouet C., et al. Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema. Allergy 2010, 65:793-795.
70. Ghebrehiwet B., Silverberg M., Kaplan A.P. Activation of the classical pathway of complement by Hageman factor fragment. JExp Med 1981, 153:665-676.
71. Ghebrehiwet B., Randazzo B.P., Dunn J.T., et al. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. JClin Invest 1983, 71:1450-1456.
72. Discipio R.G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982, 45:587-595.
73. Wiggins R.C., Giclas P.C., Henson P.M. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. JExp Med 1981, 153:1391-1404.
74. Wojta J., Kaun C., Zorn G., et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002, 100:517-523.
75. Davis A.E. The pathophysiology of hereditary angioedema. Clin Immunol 2005, 114:3-9.
76. Bossi F., Fischetti F., Pellis V., et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. JImmunol 2004, 173:6921-6927.
77. Joseph K., Ghebrehiwet B., Kaplan A.P. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol 1999, 92:246-255.
78. Cicardi M., Bergamaschini L., Zingale L.C., et al. Idiopathic nonhistaminergic angioedema. Am J Med 1999, 106:650-654.
79. Bork K., Siedlecki K., Bosch S., et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000, 75:349-354.
80. Dewald G., Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006, 343:1286-1289.
81. Duan Q.L., Binkley K., Rouleau G.A. Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. JAllergy Clin Immunol 2009, 123:906-910.
82. Gómez-Traseira C, López-Lera A, Drouet C, etal. Hereditary angioedema caused by the p.Thr309Lys mutation in the F12 gene: a multifactorial disease. J Allergy Clin Immunol, in press.
83. Hentges F., Hilger C., Kohnen M., et al. Angioedema and estrogen-dependent angioedema with activation of the contact system. JAllergy Clin Immunol 2009, 123:262-264.
84. Ghannam A, Luyasu S, Drouet C. Diagnostic et traitement de l'angioedème. EP1153239 (2011).
85. Donaldson V.H., Ratnoff O.D., Dias Da Silva W., et al. Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. JClin Invest 1969, 48:642-653.
86. Bergmann M.M., Caubet J.C., Defendi F., et al. Oestrogen-independent hereditary angioedema with normal C1 inhibitor function in a 10-year-old boy. Ann Allergy Asthma Immunol 2013, 11:67-69.
87. Guichon C., Floccard B., Coppéré B., et al. One hypovolaemic shock... two kinin pathway abnormalities. Intensive Care Med 2011, 37:1227-1228.
88. Giard C., Nicolie B., Drouet M., et al. Angio-oedema induced by oestrogen contraceptives is mediated by bradykinin and is frequently associated with urticaria. Dermatology 2012, 225:62-69.
89. Råberg L., Sim D., Read A.F. Disentangling genetic variation for resistance and tolerance to infectious diseases in animals. Science 2007, 318:812-814.
90. Maas C., Oschatz C., Renné T. The plasma contact system 2.0. Semin Thromb Hemost 2011, 37:375-381.
91. Bork P., Bairoch A. Extracellular protein modules: a proposed nomenclature. Trends Biochem Sci 1995, 20.